A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
A phase 1/2 trial of INV-6452 in ovarian cancer, endometrial cancer and HR-positive / HER2-negative breast cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.
Overview
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT07612891 by Shenzhen Ionova Life Sciences Co., Ltd., with 201 participants planned, started 2025-07-04 and due to reach its primary completion in 2028-02-04. Interventions recorded: INV-6452.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Shenzhen Ionova Life Sciences, Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Shares Shenzhen Ionova Life Sciences and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Ovarian cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialA Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.